12.061: Type I diabetes monitoring and QTc interval.
Diabetes mellitus (DM) is a common metabolic disorder characterised by high blood glucose. It is caused by a lack of pancreatic beta-cell insulin production in type 1 DM. Patients with type 1 diabetes mellitus have a seven-fold higher risk of sudden cardiac death than age-matched nondiabetic controls, although the underlying mechanism for this is unclear. Sudden cardiac death is closely linked with cardiac arrhythmia, particularly Torsades de Points (TdP) and prolongation of the QT interval is a key risk factor.
20.032: Type II diabetes monitoring and QTc interval.
Diabetes mellitus (DM) is a common metabolic disorder characterised by high blood glucose. It is caused by a reduced sensitivity of tissues to insulin in type 2 DM. Patients with type 2 diabetes mellitus may be at an increased risk of sudden cardiac death, hence this study. Sudden cardiac death is closely linked with cardiac arrhythmia, particularly Torsades de Points (TdP) and prolongation of the QT interval is a key risk factor.
21.026: Telemonitoring in cardiac amyloidosis (PATHWAY-RCT).
Cardiac amyloidosis is a condition where the heart muscle, amongst other tissues, is infiltrated by the abnormal build-up of proteins called amyloid. This stiffens and thickens the heart muscle over time which makes it less efficient and puts further stress and strain on the other chambers of the heart, leading to heart failure. Telemonitoring is the practice of monitoring patients from a distance and has been shown to reduce heart failure admissions and death in patients with heart failure from any cause. This prospective clinical study monitors the weight, the most reliable clinical sign of this fluid build-up, of patients with cardiac amyloidosis at home and intervene where a build-up of fluid is observed by telephone discussion with a doctor. This study will evaluate the effect fairly by comparing telemonitoring with usual care.
19.030: Developing a non-invasive clinical tool to predict Non-Alcoholic Fatty Liver Disease (NAFLD) in clinical trial volunteers.
NAFLD is a very common (25% of adults worldwide) and varied condition ranging from no symptoms to inflammation, scarring and cancer. In clinical trials it is important to detect fatty liver. Patients taking new medicines are monitored closely and carefully for the presence of any side-effects. Liver drug reactions are the 2nd most common reason for stopping a trial. Fatty liver can confuse or worsen a drug reaction, so being able to detect this condition makes trials safer and more effective. The development of an artificial intelligence prediction tool is the focus of this study.
22.015: Longitudinal Food Effects (LIFE) study.
Traditional approaches to understanding the effects of diet on health are performed in large observational cohorts followed up over decades. These study designs have several well-recognised flaws including expense, recall and survey bias, an inability to track food changes over time, and an inability to track important confounders, such as the food habits of co-habitants. Supermarket loyalty schemes offer a new source of historical and highly accurate purchasing habits for individuals. This large-scale study with consenting individuals who download their data and correlate this with a health questionnaire, will enable the development of an effective database of health-food outcomes.
We are studying long term immunity of individuals who have contracted COVID-19.Learn more
We are investigating how drugs affect the cardiovascular system of healthy and diseased patient populations.Learn more
We examine methods and technological innovations to improve the design of clinical trials.Learn more
We identify predictive factors for hepatic steatosis in clinical trial volunteers to help improve volunteer screening and mitigate the risks of confounding variables impacting the quality of trial data and results.Learn more
We study how individual ethnic and sex differences can affect cardiac safety assessments and biomarker analyses.Learn more